US Patent Issued to Hepagene Therapeutics (HK) on Aug. 5 for "Heterocyclic THR-Beta receptor agonist compound and preparation method and use therefor" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,378,268, issued on Aug. 5, was assigned to Hepagene Therapeutics (HK) Ltd. (Hong Kong).

"Heterocyclic THR-Beta receptor agonist compound and preparation method and use therefor" was invented by Shanghai Yu (Suzhou, China) and Ben Li (Suzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-Beta agonistic activity while also improving selectivity for THR-Alpha, thereby improving pharmaceutical quality."

The patent was filed on Oct. 19, 2020, under Application No. 17/636,331.

*For further information, including...